股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 杭州泰格醫藥科技股份有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 2. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03347 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 123,124,800 | RMB | | 1 RMB | | 123,124,800 | | 增加 / 減少 (-) | | | | 0 | | RMB | | 0 | | 本月底結存 | | | 123,124,800 | RMB | | 1 RMB | | 123,124,800 | 本月底法定/註冊股本總額： RMB 861,026,05 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 杭州泰格醫藥科技股份有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 300347 | 說明 | | 於深圳證券交易所上市 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | | 737,901,250 RMB | | 1 | RMB | | 737,901,250 | | 增加 / 減少 (-) | | | | 0 | | RMB | | | 0 | | 本月底結存 | | | | 737,901,250 RMB | | 1 RMB | | | 737,901,250 ...

Core Insights - "National Team" funds held over 800 A-shares as of the end of Q3, with significant investments in Agricultural Bank of China, Bank of China, and Industrial and Commercial Bank of China, each exceeding 1 trillion yuan in market value [1][3] - The "National Team" increased holdings in sectors such as insurance, resources, consumer goods, electronics, and telecommunications, with some stocks doubling in price during Q3 [1][8] - The funds exited from the top ten shareholders in sectors like securities, banking, electricity, real estate, and pharmaceuticals [1][8] Holdings Overview - As of the end of Q3, "National Team" funds were among the top ten shareholders in over 800 A-share companies, with 33 companies having a market value exceeding 10 billion yuan [3] - The top three holdings by market value were Agricultural Bank of China (1.11 trillion yuan), Bank of China (1.03 trillion yuan), and Industrial and Commercial Bank of China (1.02 trillion yuan) [3][5] - Other significant holdings included China International Capital Corporation, China Ping An, and New China Life Insurance, each with market values above 60 billion yuan [3][5] Sector Adjustments - In Q3, "National Team" funds entered the top ten shareholders of nearly 180 new listed companies, with notable investments in Mindray Medical, Giant Network, and Unisoc, each exceeding 1 billion yuan in market value [6] - The funds increased their positions in financial stocks such as New China Life Insurance and China Pacific Insurance, as well as resource stocks like Baosteel and China Aluminum [8] - Growth-oriented stocks that saw increased holdings included electronic companies like Pengding Holdings and Sanan Optoelectronics, with some stocks like Deep South Circuit and EVE Energy experiencing price increases around 100% [9]

Summary of Hangzhou Tigermed Consulting Conference Call Company Overview - **Company**: Hangzhou Tigermed Consulting (300347.SZ) - **Industry**: China Healthcare - **Market Capitalization**: Rmb46,720 million - **Current Stock Price**: Rmb53.54 - **Price Target**: Rmb93.10, indicating a potential upside of 74% [7][10] Key Financial Highlights - **3Q25 Revenue**: Rmb1,775 million, up 3.9% YoY - **3Q25 Earnings**: Rmb637 million, up 98.7% YoY - **Recurring Earnings**: Rmb115 million, down 54.3% YoY - **Net New Orders Backlog**: Rmb7.0 billion, up approximately 15% YoY [3][10] Core Insights - **Recovery Cycle**: The company is entering a recovery phase as old projects are phased out, with a sequential revenue improvement of 5% in 3Q25. However, margins are still pressured due to declining average unit prices YoY against a fixed cost base [3][4] - **New Orders Composition**: In 3Q25, 30.3% of new orders by value came from multinational pharma companies, while 17.5% came from large Chinese pharma [3] - **Clinical Trials**: There was an increase in new orders from Phase 1-2 clinical trials, reflecting improved funding conditions. Management noted a clear recovery in private financing during 3Q25, with aggregate financing in China reaching its highest value for a single quarter since 2022 [3][4] Industry Dynamics - **CRO Industry Growth**: The global biopharma sector is re-accelerating investments in R&D and clinical trials, with China's CROs providing cost and efficiency advantages. Key drivers include: - Increased private financing activity supporting preclinical and early-phase drug pipelines - Robust out-licensing activity in China, which is driving trial starts for additional indications and replenishing cash reserves of local biotechs [4] - **Industry Consolidation**: Potential normalization of supply and average prices due to industry consolidation, as evidenced by a peer's recent divestment of its CRO segment [5] Risks and Considerations - **Upside Risks**: Faster growth in clinical R&D outsourcing, accelerated recovery of domestic demand, and new collaboration deals [13] - **Downside Risks**: Slower-than-expected recovery in clinical CRO demand, rising pricing pressure, geopolitical and currency risks, and potential impairment of goodwill and intangible assets [13] Valuation Metrics - **EPS Estimates**: Expected EPS for FY25 is Rmb0.96, with projections of Rmb1.29 for FY26 and Rmb1.99 for FY27 [7] - **P/E Ratio**: Projected P/E ratios are 107.5 for FY25, decreasing to 25.3 by FY27 [7] - **ROE**: Expected ROE is projected to increase from 2.1% in FY25 to 8.3% by FY27 [7] Conclusion Hangzhou Tigermed Consulting is positioned to benefit from a recovery in the biopharma sector, supported by increasing private financing and a growing backlog of new orders. The company’s strategic focus on early-phase clinical trials and the advantages offered by China's CRO landscape are expected to drive future growth, despite potential risks associated with market dynamics and competition.

Market Overview - The market experienced fluctuations last week, with the China Securities Xinhua National Brand Index closing at 2029.92 points [1] - The Shanghai Composite Index rose by 0.11%, the Shenzhen Component Index increased by 0.67%, and the ChiNext Index went up by 0.50%, while the CSI 300 Index fell by 0.43% and the brand index decreased by 0.38% [2] Strong Performers - Several constituent stocks showed strong performance last week, with Kingsoft Office rising by 18.09%, Sunshine Power increasing by 15.03%, and Tigermed, Xilitai, and China National Pharmaceutical Group rising by 13.93%, 10.80%, and 7.87% respectively [2] - Other notable performers included Salt Lake Industry, Guocera Materials, and iFlytek, which all saw increases of over 6% [2] Year-to-Date Performance - Since the beginning of the second half of the year, Zhongji Xuchuang has surged by 224.62%, followed by Sunshine Power at 181.89%, and Yiwei Lithium Energy and Zhaoyi Innovation with increases of 82.17% and 74.36% respectively [3] - Other companies such as Lanke Technology and Wuwei Biological have also shown significant gains of over 60% [3] Market Sentiment and Future Outlook - Market volatility has increased significantly since October, with major growth sectors experiencing corrections [4] - Investment perspectives suggest that despite previous gains, quality companies' fluctuations may present buying opportunities [4] - The market is expected to transition from liquidity-driven growth to fundamentals-driven growth, with a strong likelihood of economic recovery supported by ongoing policy efforts [4]

Market Performance - The market experienced fluctuations last week, with the China Securities Index closing at 2029.92 points, a decrease of 0.38% [1] - The Shanghai Composite Index rose by 0.11%, while the Shenzhen Component Index increased by 0.67% and the ChiNext Index went up by 0.50% [1] Strong Performing Stocks - Several constituent stocks performed strongly last week, with Kingsoft Office leading with an increase of 18.09%, followed by Sungrow Power with 15.03% [1] - Other notable performers included Tigermed, Sinopharm, and China Duty Free, which rose by 13.93%, 10.80%, and 7.87% respectively [1] Year-to-Date Performance - Since the beginning of the second half of the year, Zhongji Xuchuang has surged by 224.62%, ranking first in terms of growth, while Sungrow Power has increased by 181.89% [2] - Other significant gainers include Yiwei Lithium Energy and Zhaoyi Innovation, which rose by 82.17% and 74.36% respectively [2] Market Outlook - The market is expected to face continued fluctuations and structural adjustments in the short term, but the medium-term outlook remains positive, transitioning from liquidity-driven to fundamentals-driven growth [1][3] - The release of macroeconomic policies and the completion of Q3 earnings reports may lead to a temporary lack of new driving forces, resulting in increased sector rotation [3] Investment Perspective - Despite recent volatility, high-quality companies' fluctuations are viewed as buying opportunities, indicating that Chinese assets still hold significant investment potential [2] - The ongoing policy support is likely to drive economic recovery, which could further strengthen the stock market as corporate earnings improve [3]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical sector [7] Core Views - The pharmaceutical sector has shown resilience with a 1.2% increase in the CITIC Pharmaceutical Index, outperforming the CSI 300 Index by 1.6 percentage points during the week of October 27-31, 2025 [3][54] - The overall revenue growth for the pharmaceutical sector in Q1-Q3 2025 was -2%, with a net profit decline of -1%. However, Q3 2025 showed signs of improvement with a 0% revenue growth and a -3% net profit growth compared to Q2 2025 [4][17] - The report highlights the strong performance of innovative drugs, CXO, and upstream sectors, indicating a positive outlook for these segments [4][25] Summary by Sections Weekly Market Review - The CITIC Pharmaceutical Index increased by 1.2% during the week, ranking 13th among CITIC's primary industry classifications. Year-to-date, the index has risen by 22%, also ranking 13th [3][54] - The top five performing stocks for the week included HeFu China (+49.0%), NuoSiGe (+36.7%), SanSheng GuoJian (+33.1%), ChangShan Pharmaceutical (+29.6%), and ZhenDe Medical (+26.6%) [3][70] Q3 Performance Overview - The pharmaceutical sector's overall revenue growth for Q3 2025 was 0%, with a net profit decline of -3%. The highest revenue growth was seen in Bio-Tech, Bio-Pharma, and home-use devices [4][17] - The report notes that the Bio-Pharma segment has consistently shown strong revenue growth since Q1 2023, indicating a robust performance trend [18][25] Subsector Analysis 1. **BioPharma/Biotech** - Q3 2025 saw significant growth due to multiple innovative drug approvals, with expectations for continued high growth in 2026 [25] 2. **Pharma** - The sector faced challenges with a -1% revenue decline in Q3 2025, but upcoming healthcare negotiations may provide revenue boosts [26] 3. **CXO** - The CXO sector reported a 10% revenue increase and a 51% net profit increase in Q3 2025, with a positive outlook for Q4 and 2026 [31] 4. **Upstream** - The upstream sector's revenue reached 4.4 billion yuan in Q3 2025, showing a 13.1% year-on-year growth, with expectations for further growth in 2026 [30] 5. **Medical Devices** - The medical devices sector reported a 10.6% revenue increase in Q3 2025, with a positive outlook for continued growth [41] Recommendations - The report suggests focusing on high-quality innovative drug leaders and the CXO sector, particularly companies like SanSheng Pharmaceutical, XinDa Bio, and Kangfang Bio [5][25]

Core Insights - Boji Pharmaceutical is a leading provider of new drug research and development outsourcing services in China, established in 2002 and listed on the Shenzhen Stock Exchange in 2015 [1] Group 1: Business Overview - Boji Pharmaceutical offers comprehensive new drug R&D services, including preclinical research, clinical research, technology transfer, and consulting services [1] - The company operates in the pharmaceutical and biotechnology sector, specifically in medical services and R&D outsourcing, with relevant concepts including Helicobacter pylori and hepatitis treatment [1] Group 2: Financial Performance - For Q3 2025, Boji Pharmaceutical reported revenue of 584 million yuan, ranking 16th out of 29 in the industry, significantly lower than the top competitor WuXi AppTec at 32.857 billion yuan [2] - The net profit for the same period was 23.8675 million yuan, placing the company 21st in the industry, again far behind WuXi AppTec's 12.206 billion yuan [2] Group 3: Financial Ratios - As of Q3 2025, Boji Pharmaceutical's debt-to-asset ratio was 33.62%, higher than the previous year's 31.81% and above the industry average of 22.79% [3] - The gross profit margin was 28.83%, down from 32.19% year-on-year and below the industry average of 37.70% [3] Group 4: Leadership and Shareholder Information - The chairman and controlling shareholder, Wang Tingchun, saw his salary decrease from 414,000 yuan in 2023 to 391,000 yuan in 2024 [4] - As of September 30, 2025, the number of A-share shareholders increased by 18.91% to 29,600, while the average number of circulating A-shares held per shareholder decreased by 15.21% [5] Group 5: Business Developments - Clinical business showed stable growth with clinical research service revenue of 290 million yuan and new contract value of 752 million yuan, achieving a business gross margin of 30.6% [5] - Non-clinical business performance varied, with preclinical research service revenue at 40.87 million yuan and other consulting services at 23.49 million yuan [5] - The company has made progress in self-developed projects, including innovative traditional Chinese medicine [5]

Core Insights - The Biotech Index (970038) closed at 2279.35 points, up 0.77%, with a trading volume of 28.709 billion yuan and a turnover rate of 1.85% [1] - Among the index constituents, 41 stocks rose, with Hualan Vaccine leading at a 17.88% increase, while 8 stocks fell, with Deep Technology leading the decline at 6.38% [1] Index Performance - The Biotech Index saw a net inflow of 140 million yuan from institutional investors, while retail investors contributed a net inflow of 210 million yuan, and there was a net outflow of 350 million yuan from speculative funds [1] Top Constituents - The top ten constituents of the Biotech Index include: - Mindray Medical (sz300760) with a weight of 13.81%, latest price at 215.04, and a decrease of 0.76% [1] - Changchun High-tech (sz000661) with a weight of 5.41%, latest price at 112.26, and a decrease of 2.55% [1] - Kanglong Chemical (sz300759) with a weight of 4.66%, latest price at 33.51, and an increase of 1.12% [1] - Other notable constituents include Muyuans (sz002714) and Aimeike (sz300896) with respective weights of 3.66% and 3.44% [1] Capital Flow Details - Detailed capital flow for key stocks includes: - Mindray Medical saw a net inflow of 26.2 million yuan from institutional investors [2] - Muyuans had a net inflow of 203 million yuan from institutional investors [2] - Hualan Vaccine experienced a net inflow of 74.8 million yuan from institutional investors [2]

Core Points - The Medical Health R Index (480016) closed at 7755.61 points, up 1.68%, with a total transaction volume of 40.103 billion yuan and a turnover rate of 1.25% [1] - Among the index constituents, 43 stocks rose, with Zai Jian Pharmaceutical leading with a 16.14% increase, while 6 stocks fell, with Kailai Ying leading the decline at 4.33% [1] Index Constituents Summary - The top ten constituents of the Medical Health R Index include: - WuXi AppTec (603259) with a weight of 14.37%, latest price at 99.40 yuan, and a 2.41% increase, total market value of 296.585 billion yuan [1] - Hengrui Medicine (600276) with a weight of 11.45%, latest price at 64.15 yuan, and a 2.02% increase, total market value of 425.776 billion yuan [1] - Mindray Medical (300760) with a weight of 8.07%, latest price at 215.04 yuan, and a 0.76% decrease, total market value of 260.723 billion yuan [1] - United Imaging Healthcare (688271) with a weight of 4.32%, latest price at 139.92 yuan, and a 0.79% decrease, total market value of 115.316 billion yuan [1] - Pianzai Shou (600436) with a weight of 3.59%, latest price at 178.13 yuan, and a 0.64% increase, total market value of 107.469 billion yuan [1] - Aier Eye Hospital (300015) with a weight of 3.21%, latest price at 12.25 yuan, and a 1.16% increase, total market value of 114.236 billion yuan [1] - Kelun Pharmaceutical (002422) with a weight of 2.54%, latest price at 35.00 yuan, and a 2.19% increase, total market value of 55.932 billion yuan [1] - Changchun High-tech (000661) with a weight of 2.35%, latest price at 112.26 yuan, and a 2.55% decrease, total market value of 45.795 billion yuan [1] - Fosun Pharma (600196) with a weight of 2.28%, latest price at 29.20 yuan, and a 2.46% increase, total market value of 77.977 billion yuan [1] - New Hope Liuhe (002001) with a weight of 2.22%, latest price at 24.30 yuan, and a 0.04% increase, total market value of 74.684 billion yuan [1] Capital Flow Summary - The net inflow of main funds into the Medical Health R Index constituents totaled 406 million yuan, while speculative funds saw a net outflow of 644 million yuan, and retail investors had a net inflow of 237 million yuan [1] - Specific capital flow details for key stocks include: - Mindray Medical (300760) with a main fund net inflow of 262 million yuan and a speculative fund net outflow of 127 million yuan [2] - BeiGene (688235) with a main fund net inflow of 233 million yuan and a speculative fund net outflow of 225 million yuan [2] - Haizhi Pharmaceutical (002653) with a main fund net inflow of 92.778 million yuan and a retail net outflow of 95.916 million yuan [2] - New Hope Liuhe (002001) with a main fund net inflow of 90.378 million yuan and a speculative fund net outflow of 43.538 million yuan [2] - Renfu Pharmaceutical (600079) with a main fund net inflow of 71.683 million yuan and a speculative fund net outflow of 41.302 million yuan [2]